Skip to content

Genetic Architecture of Radiotherapy Toxicity and Prognosis (GARTP)

A Genetic Study of Recurrence, Metastasis and Radiation-induced Normal Tissue Injury in Nasopharyngeal Carcinoma:A Prospective Observational Clinical Study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-ROC-17012658
Enrollment
Unknown
Registered
2017-09-13
Start date
2005-07-01
Completion date
Unknown
Last updated
2017-10-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Recurrence, Metastasis and Radiation-induced Normal Tissue Injury of Nasopharyngeal Carcinoma

Interventions

1:NULL

Sponsors

Sun Yat-sen University Cancer Center
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patient is pathologically confirmed NPC with information of clinical stage and TNM classification; 2. Patient is expected to have survival time of more than six months; 3. The functional state score (KPS) is no less than 70; 4. Patient aged 18-80 years; 5. Patient has complete medical records including medical history, result of physical examination and other related examination, etc.; 6. Patient agrees to participate in this clinical study and sign the informed consent.

Exclusion criteria

Exclusion criteria: The patients who are in any of these cases should be excluded: 1. The patient does not complete all the courses of radiotherapy; 2. The patient is not compliant with follow-up for some reasons; 3. The patient has metastatic tumor when he/she is diagnosed with NPC; 4. There are abnormal signals in the MRI of nasopharynx/brain for some unknown reasons; 5. The patient has been treated with head and neck radiotherapy for other diseases (not including NPC); 6. The patient has suffered from the diseases that have similar clinical symptoms with radiation early effect. For example, the patient had salivary gland surgery or other physical treatment.

Design outcomes

Primary

MeasureTime frame
recurrence;metastasis;radiation toxicity;

Secondary

MeasureTime frame
clinical stage;treatment modality;

Countries

China

Contacts

Public ContactJia Wei-Hua

Sun Yat-Sen University Cancer Center

jiaweih@sysu.edu.cn+86 13609747580

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026